Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Neoplasms 1Mycosis Fungoides 1Mycoses 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × ProMune × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡